Immix Biopharma (NASDAQ:IMMX) Issues Earnings Results

Immix Biopharma (NASDAQ:IMMX) issued its quarterly earnings results on Tuesday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08), Zacks reports.

Immix Biopharma Trading Up 2.9 %

Shares of NASDAQ:IMMX traded up $0.05 during trading on Thursday, reaching $1.62. 6,793 shares of the company traded hands, compared to its average volume of 177,367. The firm has a market capitalization of $44.33 million, a price-to-earnings ratio of -1.90 and a beta of 0.11. The business’s fifty day moving average is $1.66 and its 200-day moving average is $1.97. Immix Biopharma has a 52-week low of $1.26 and a 52-week high of $7.75.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Immix Biopharma in a research note on Thursday, October 3rd.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.